Patient Care Prostate Cancer Clinical Trials Urology
James Bird gets emotional talking about it. How he qualified for a clinical trial that, in his view, preserved his manhood after he was diagnosed with prostate cancer in late 2022.
“The day I went in to see if I qualified, there were 10 other guys out there in the lobby who didn’t get into the trial,” he says. “I felt so sorry for them. One of the technicians who was involved with the trial told me he was getting calls from all over, from guys begging to get in. That’s how important this is.”
Patient Care Community Kidney Cancer Urology
To start with, there was his usual schedule of national travel for his job as a Wall Street journeyman – he was always flying somewhere. Add to that moving to Castle Rock from San Francisco, plus a love for concerts and baseball games and whatever else life offers, and it’s no wonder that Lincoln Yersin was feeling run down.
But this run down? This exhausted? He went to see his primary care provider in San Francisco a few times, had a few tests, and the diagnosis was stress.
Awareness Bladder Cancer Urology
In its early stages, bladder cancer can be easy to ignore or write off as something it isn’t – a UTI, a bladder infection, or other conditions that are commonly treated with an antibiotic.
Research Pediatric Cancer Kidney Cancer Urology
A longstanding approach to surgeries for children with kidney tumors has been an abundance of caution.
Community Awareness Urology Testicular cancer
Testicular cancer is a highly treatable cancer that isn’t always easy to talk about.
Former Denver Broncos running back Ronnie Hillman, 31, died Wednesday of a rare type of kidney cancer that disproportionately impacts young people who are Black with sickle cell trait or sickle cell disease.
Prostate Cancer Magazine Urology
It was all his grandma’s doing, says University of Colorado Cancer Center member Paul Maroni, MD.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Greg Glasgow
